Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library
- PMID: 20105447
- DOI: 10.1016/j.humimm.2010.01.021
Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library
Abstract
Human leukocyte antigen (HLA)-DQ2 (DQA1 x 0501/DQB1 x 0201) is associated with several immune disorders, including celiac disease, which is caused by an inappropriate T-cell response to gluten. Interference with peptide presentation by HLA-DQ2, for example, by the use of peptide blockers, is a possible treatment strategy for such HLA-associated disorders. A successful implementation of this strategy will depend on the identification of ligands that bind much better to HLA-DQ2 than the disease related epitopes. We have used a positional scanning nonapeptide library to determine the optimal amino acids for each position of the HLA-DQ2 binding frame. By combining the optimal residues in each position, we were able to design high affinity binders to HLA-DQ2. Interestingly, the decapeptide with highest affinity was composed of the most favorable residues in each position. This sequence bound 50-fold better than the immunodominant gluten epitope DQ2-alpha-I-gliadin, which makes it an interesting lead compound for the development of blockers. For some natural HLA-DQ2 ligands, the correlation between measured and predicted affinities was poorer, but notably these peptides did not have optimal amino acids at all positions. Our approach represents a straightforward strategy for developing high-affinity binders to HLA class II molecules.
Copyright 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule.Mol Immunol. 2010 Feb;47(5):1091-7. doi: 10.1016/j.molimm.2009.10.036. Epub 2009 Dec 3. Mol Immunol. 2010. PMID: 19962195
-
Modelling of HLA-DQ2 and its interaction with gluten peptides to explain molecular recognition in celiac disease.J Mol Graph Model. 2005 Apr;23(5):419-31. doi: 10.1016/j.jmgm.2004.12.002. Epub 2005 Jan 18. J Mol Graph Model. 2005. PMID: 15781184
-
Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2.Biochemistry. 2005 Mar 22;44(11):4442-9. doi: 10.1021/bi047747c. Biochemistry. 2005. PMID: 15766274
-
The molecular basis of celiac disease.J Mol Recognit. 2003 Sep-Oct;16(5):333-6. doi: 10.1002/jmr.641. J Mol Recognit. 2003. PMID: 14523946 Review.
-
[The identification of the immunodominant gliadin epitope].Harefuah. 2003 Jul;142(7):554-7, 564. Harefuah. 2003. PMID: 12908394 Review. Hebrew.
Cited by
-
Therapeutic approaches for celiac disease.Best Pract Res Clin Gastroenterol. 2015 Jun;29(3):503-21. doi: 10.1016/j.bpg.2015.04.005. Epub 2015 May 9. Best Pract Res Clin Gastroenterol. 2015. PMID: 26060114 Free PMC article. Review.
-
Coeliac Disease - New Pathophysiological Findings and Their Implications for Therapy.Viszeralmedizin. 2014 Jun;30(3):156-65. doi: 10.1159/000365099. Viszeralmedizin. 2014. PMID: 26288589 Free PMC article. Review.
-
The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet.Semin Immunopathol. 2012 Jul;34(4):581-600. doi: 10.1007/s00281-012-0318-8. Epub 2012 Jun 7. Semin Immunopathol. 2012. PMID: 22674144 Review.
-
Review article: coeliac disease, new approaches to therapy.Aliment Pharmacol Ther. 2012 Apr;35(7):768-81. doi: 10.1111/j.1365-2036.2012.05013.x. Epub 2012 Feb 13. Aliment Pharmacol Ther. 2012. PMID: 22324389 Free PMC article. Review.
-
Novel therapies for coeliac disease.J Intern Med. 2011 Jun;269(6):604-13. doi: 10.1111/j.1365-2796.2011.02376.x. J Intern Med. 2011. PMID: 21401739 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials